Teacher Retirement System of Texas Cuts Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Teacher Retirement System of Texas cut its stake in Teva by 15.5% in Q4, selling 108,345 shares and now holding 589,229 shares worth about $18.39 million (≈0.05% of the company).
• Teva posted stronger-than-expected Q results (EPS $0.96 vs. $0.65 estimate; revenue $4.71B, +11.4% YoY), provided FY2026 EPS guidance of 2.57–2.77, and several analysts raised price targets, leaving a MarketBeat consensus of "Moderate Buy" with an average target of $38.78.
• Insider selling has been notable, with ~920,901 shares sold (~$30.06M) over the last three months, while institutional investors own about 54.05% of the stock and insiders hold roughly 0.54%.

Teacher Retirement System of Texas lessened its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 15.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 589,229 shares of the company's stock after selling 108,345 shares during the quarter. Teacher Retirement System of Texas owned 0.05% of Teva Pharmaceutical Industries worth $18,390,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Grove Bank & Trust boosted its holdings in Teva Pharmaceutical Industries by 300.0% in the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company's stock worth $31,000 after acquiring an additional 750 shares in the last quarter. Cromwell Holdings LLC boosted its holdings in Teva Pharmaceutical Industries by 40.3% in the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company's stock worth $44,000 after acquiring an additional 629 shares in the last quarter. Rothschild Investment LLC boosted its holdings in Teva Pharmaceutical Industries by 97.0% in the third quarter. Rothschild Investment LLC now owns 2,738 shares of the company's stock worth $55,000 after acquiring an additional 1,348 shares in the last quarter. JFS Wealth Advisors LLC boosted its holdings in Teva Pharmaceutical Industries by 257.1% in the third quarter. JFS Wealth Advisors LLC now owns 2,778 shares of the company's stock worth $56,000 after acquiring an additional 2,000 shares in the last quarter. Finally, LRI Investments LLC boosted its holdings in Teva Pharmaceutical Industries by 246.0% in the third quarter. LRI Investments LLC now owns 2,813 shares of the company's stock worth $57,000 after acquiring an additional 2,000 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Teva Pharmaceutical Industries Trading Down 1.8%

Teva Pharmaceutical Industries stock opened at $30.66 on Friday. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89. Teva Pharmaceutical Industries Ltd. has a 52 week low of $14.52 and a 52 week high of $37.35. The company has a market capitalization of $35.25 billion, a price-to-earnings ratio of 25.55, a price-to-earnings-growth ratio of 2.73 and a beta of 0.76. The stock has a 50-day moving average price of $31.22 and a 200 day moving average price of $28.96.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, topping analysts' consensus estimates of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The firm had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.36 billion. During the same quarter in the previous year, the company posted $0.71 earnings per share. The company's revenue was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.62 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Truist Financial raised their price target on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a "buy" rating in a report on Wednesday, February 18th. Wall Street Zen raised Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a report on Saturday, January 31st. Barclays raised their price target on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an "overweight" rating in a report on Friday, January 30th. The Goldman Sachs Group raised their price target on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a "buy" rating in a report on Monday, February 9th. Finally, Piper Sandler reissued an "overweight" rating and issued a $41.00 price target (up from $40.00) on shares of Teva Pharmaceutical Industries in a report on Wednesday, March 4th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $38.78.

Insider Activity

In related news, insider Brian Savage sold 1,127 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $31.67, for a total transaction of $35,692.09. Following the completion of the sale, the insider owned 10,914 shares of the company's stock, valued at $345,646.38. The trade was a 9.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Richard Daniell sold 17,295 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $31.67, for a total value of $547,732.65. Following the sale, the executive vice president directly owned 85,755 shares of the company's stock, valued at $2,715,860.85. This trade represents a 16.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 920,901 shares of company stock valued at $30,056,789. 0.54% of the stock is owned by insiders.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.